{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:08:48Z","timestamp":1793664528249,"version":"4.5.1"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,9,28]],"date-time":"2015-09-28T00:00:00Z","timestamp":1443398400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s12016-015-8515-6","type":"journal-article","created":{"date-parts":[[2015,9,28]],"date-time":"2015-09-28T06:33:37Z","timestamp":1443422017000},"page":"1-15","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Bone as a Target Organ in Rheumatic Disease: Impact on Osteoclasts and Osteoblasts"],"prefix":"10.1007","volume":"51","author":[{"given":"Rebecca","family":"Baum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M.","family":"Gravallese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,28]]},"reference":[{"key":"8515_CR1","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrrheum.2012.153","volume":"8","author":"G Schett","year":"2012","unstructured":"Schett G, Gravallese E (2012) Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol 8:656\u2013664","journal-title":"Nat Rev Rheumatol"},{"key":"8515_CR2","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/1529-0131(200010)43:10<2143::AID-ANR1>3.0.CO;2-S","volume":"43","author":"EM Gravallese","year":"2000","unstructured":"Gravallese EM, Goldring SR (2000) Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 43:2143\u20132151","journal-title":"Arthritis Rheum"},{"key":"8515_CR3","volume-title":"The role of the immune system in the local and systemic bone loss in inflammatory arthritis, in Osteimmunology: interaction of the Immune and skeletal systems","author":"EM Gravallese","year":"2015","unstructured":"Gravallese EM, Goldring SR, Schett G (2015) The role of the immune system in the local and systemic bone loss in inflammatory arthritis, in Osteimmunology: interaction of the Immune and skeletal systems, 2nd edn. Academic Press, London, Burlington MA, San Diego CA","edition":"2"},{"key":"8515_CR4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/rheumatology\/35.4.309","volume":"35","author":"AA Deodhar","year":"1996","unstructured":"Deodhar AA, Woolf AD (1996) Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol 35:309\u2013322","journal-title":"Br J Rheumatol"},{"key":"8515_CR5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.bor.0000127824.42507.68","volume":"16","author":"NC Walsh","year":"2004","unstructured":"Walsh NC, Gravallese EM (2004) Bone loss in inflammatory arthritis: mechanisms and treatment strategies. Curr Opin Rheumatol 16:419\u2013427","journal-title":"Curr Opin Rheumatol"},{"key":"8515_CR6","first-page":"1282","volume":"18","author":"K Aho","year":"1991","unstructured":"Aho K, Heliovaara M, Maatela J, Tuomi T, Palosuo T (1991) Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol 18:1282\u20131284","journal-title":"J Rheumatol"},{"key":"8515_CR7","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1002\/art.11223","volume":"48","author":"S Rantapaa-Dahlqvist","year":"2003","unstructured":"Rantapaa-Dahlqvist S, de Jong BA, Berglin E et al (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741\u20132749","journal-title":"Arthritis Rheum"},{"key":"8515_CR8","doi-asserted-by":"crossref","first-page":"R159","DOI":"10.1186\/ar4342","volume":"15","author":"EV Arkema","year":"2013","unstructured":"Arkema EV, Goldstein BL, Robinson W et al (2013) Anti-citrullinated peptide autoantibodies, human leukocyte antigen shared epitope and risk of future rheumatoid arthritis: a nested case\u2013control study. Arthritis Res Ther 15:R159","journal-title":"Arthritis Res Ther"},{"key":"8515_CR9","doi-asserted-by":"crossref","first-page":"728610","DOI":"10.1155\/2015\/728610","volume":"2015","author":"AA Jilani","year":"2015","unstructured":"Jilani AA, Mackworth-Young CG (2015) The role of citrullinated protein antibodies in predicting erosive disease in rheumatoid arthritis: a systematic literature review and meta-analysis. Int J Rheumatol 2015:728610","journal-title":"Int J Rheumatol"},{"key":"8515_CR10","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/annrheumdis-2012-202958","volume":"73","author":"A Kleyer","year":"2014","unstructured":"Kleyer A, Finzel S, Rech J et al (2014) Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis 73:854\u2013860","journal-title":"Ann Rheum Dis"},{"key":"8515_CR11","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/S0002-9440(10)63016-7","volume":"159","author":"AR Pettit","year":"2001","unstructured":"Pettit AR, Ji H, von Stechow D et al (2001) TRANCE\/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 159:1689\u20131699","journal-title":"Am J Pathol"},{"key":"8515_CR12","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1172\/JCI0215582","volume":"110","author":"K Redlich","year":"2002","unstructured":"Redlich K, Hayer S, Ricci R et al (2002) Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 110:1419\u20131427","journal-title":"J Clin Invest"},{"key":"8515_CR13","first-page":"943","volume":"152","author":"EM Gravallese","year":"1998","unstructured":"Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR (1998) Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 152:943\u2013951","journal-title":"Am J Pathol"},{"key":"8515_CR14","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/46303","volume":"402","author":"YY Kong","year":"1999","unstructured":"Kong YY, Feige U, Sarosi I et al (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304\u2013309","journal-title":"Nature"},{"key":"8515_CR15","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P","volume":"43","author":"EM Gravallese","year":"2000","unstructured":"Gravallese EM, Manning C, Tsay A et al (2000) Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 43:250\u2013258","journal-title":"Arthritis Rheum"},{"key":"8515_CR16","doi-asserted-by":"crossref","first-page":"R76","DOI":"10.1186\/ar1943","volume":"8","author":"H Ideguchi","year":"2006","unstructured":"Ideguchi H, Ohno S, Hattori H, Senuma A, Ishigatsubo Y (2006) Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying antirheumatic drugs. Arthritis Res Ther 8:R76","journal-title":"Arthritis Res Ther"},{"key":"8515_CR17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.0105-2896.2009.00857.x","volume":"233","author":"NC Walsh","year":"2010","unstructured":"Walsh NC, Gravallese EM (2010) Bone remodeling in rheumatic disease: a question of balance. Immunol Rev 233:301\u2013312","journal-title":"Immunol Rev"},{"issue":"Suppl 1","key":"8515_CR18","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/1478-6354-13-S1-S4","volume":"13","author":"G Schett","year":"2011","unstructured":"Schett G, Coates LC, Ash ZR, Finzel S, Conaghan PG (2011) Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res Ther 13(Suppl 1):S4","journal-title":"Arthritis Res Ther"},{"key":"8515_CR19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/TACG.S37325","volume":"7","author":"FW Tsui","year":"2014","unstructured":"Tsui FW, Tsui HW, Akram A, Haroon N, Inman RD (2014) The genetic basis of ankylosing spondylitis: new insights into disease pathogenesis. Appl Clin Genet 7:105\u2013115","journal-title":"Appl Clin Genet"},{"key":"8515_CR20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13075-015-0640-3","volume":"17","author":"O FitzGerald","year":"2015","unstructured":"FitzGerald O, Haroon M, Giles JT, Winchester R (2015) Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res Ther 17:115","journal-title":"Arthritis Res Ther"},{"key":"8515_CR21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/ar2642","volume":"11","author":"RJ Lories","year":"2009","unstructured":"Lories RJ, Luyten FP, de Vlam K (2009) Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther 11:221","journal-title":"Arthritis Res Ther"},{"key":"8515_CR22","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/art.1780270902","volume":"27","author":"M Bromley","year":"1984","unstructured":"Bromley M, Woolley DE (1984) Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum 27:968\u2013975","journal-title":"Arthritis Rheum"},{"key":"8515_CR23","first-page":"1154","volume":"25","author":"Y Suzuki","year":"1998","unstructured":"Suzuki Y, Nishikaku F, Nakatuka M, Koga Y (1998) Osteoclast-like cells in murine collagen induced arthritis. J Rheumatol 25:1154\u20131160","journal-title":"J Rheumatol"},{"key":"8515_CR24","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/1529-0131(200004)43:4<821::AID-ANR12>3.0.CO;2-T","volume":"43","author":"E Romas","year":"2000","unstructured":"Romas E, Bakharevski O, Hards DK et al (2000) Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum 43:821\u2013826","journal-title":"Arthritis Rheum"},{"key":"8515_CR25","first-page":"751","volume":"13","author":"T Kuratani","year":"1998","unstructured":"Kuratani T, Nagata K, Kukita T, Hotokebuchi T, Nakasima A, Iijima T (1998) Induction of abundant osteoclast-like multinucleated giant cells in adjuvant arthritic rats with accompanying disordered high bone turnover. Histol Histopathol 13:751\u2013759","journal-title":"Histol Histopathol"},{"key":"8515_CR26","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1002\/art.11150","volume":"48","author":"G Schett","year":"2003","unstructured":"Schett G, Redlich K, Hayer S et al (2003) Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum 48:2042\u20132051","journal-title":"Arthritis Rheum"},{"key":"8515_CR27","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0002-9440(10)64417-3","volume":"161","author":"E Romas","year":"2002","unstructured":"Romas E, Sims NA, Hards DK et al (2002) Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 161:1419\u20131427","journal-title":"Am J Pathol"},{"key":"8515_CR28","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/art.20384","volume":"50","author":"P Herrak","year":"2004","unstructured":"Herrak P, Gortz B, Hayer S et al (2004) Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum 50:2327\u20132337","journal-title":"Arthritis Rheum"},{"key":"8515_CR29","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/art.20382","volume":"50","author":"NA Sims","year":"2004","unstructured":"Sims NA, Green JR, Glatt M et al (2004) Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum 50:2338\u20132346","journal-title":"Arthritis Rheum"},{"key":"8515_CR30","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1002\/art.21824","volume":"54","author":"SJ Jarrett","year":"2006","unstructured":"Jarrett SJ, Conaghan PG, Sloan VS et al (2006) Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 54:1410\u20131414","journal-title":"Arthritis Rheum"},{"key":"8515_CR31","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/acr.20004","volume":"62","author":"A Deodhar","year":"2010","unstructured":"Deodhar A, Dore RK, Mandel D et al (2010) Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 62:569\u2013574","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8515_CR32","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/art.23417","volume":"58","author":"SB Cohen","year":"2008","unstructured":"Cohen SB, Dore RK, Lane NE et al (2008) Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58:1299\u20131309","journal-title":"Arthritis Rheum"},{"key":"8515_CR33","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00198-014-2964-2","volume":"26","author":"T Sugimoto","year":"2015","unstructured":"Sugimoto T, Matsumoto T, Hosoi T et al (2015) Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT). Osteoporos Int 26:765\u2013774","journal-title":"Osteoporos Int"},{"key":"8515_CR34","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1172\/JCI200523394","volume":"115","author":"S Wei","year":"2005","unstructured":"Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL (2005) IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 115:282\u2013290","journal-title":"J Clin Invest"},{"key":"8515_CR35","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.4049\/jimmunol.160.7.3513","volume":"160","author":"DV Jovanovic","year":"1998","unstructured":"Jovanovic DV, Di Battista JA, Martel-Pelletier J et al (1998) IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 160:3513\u20133521","journal-title":"J Immunol"},{"key":"8515_CR36","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI5703","volume":"103","author":"S Kotake","year":"1999","unstructured":"Kotake S, Udagawa N, Takahashi N et al (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103:1345\u20131352","journal-title":"J Clin Invest"},{"key":"8515_CR37","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.4049\/jimmunol.170.5.2655","volume":"170","author":"E Lubberts","year":"2003","unstructured":"Lubberts E, van den Bersselaar L, Oppers-Walgreen B et al (2003) IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand\/osteoprotegerin balance. J Immunol 170:2655\u20132662","journal-title":"J Immunol"},{"key":"8515_CR38","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/rheumatology\/ken363","volume":"47","author":"M Hashizume","year":"2008","unstructured":"Hashizume M, Hayakawa N, Mihara M (2008) IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology (Oxford) 47:1635\u20131640","journal-title":"Rheumatology (Oxford)"},{"key":"8515_CR39","doi-asserted-by":"crossref","first-page":"11846","DOI":"10.1074\/jbc.M512624200","volume":"281","author":"Z Yao","year":"2006","unstructured":"Yao Z, Li P, Zhang Q et al (2006) Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression. J Biol Chem 281:11846\u201311855","journal-title":"J Biol Chem"},{"key":"8515_CR40","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1006\/excr.1998.4320","volume":"247","author":"E Jimi","year":"1999","unstructured":"Jimi E, Nakamura I, Duong LT et al (1999) Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts\/stromal cells. Exp Cell Res 247:84\u201393","journal-title":"Exp Cell Res"},{"key":"8515_CR41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2249.2010.04276.x","volume":"163","author":"M Suzuki","year":"2011","unstructured":"Suzuki M, Hashizume M, Yoshida H, Shiina M, Mihara M (2011) Intercellular adhesion molecule-1 on synovial cells attenuated interleukin-6-induced inhibition of osteoclastogenesis induced by receptor activator for nuclear factor kappaB ligand. Clin Exp Immunol 163:88\u201395","journal-title":"Clin Exp Immunol"},{"key":"8515_CR42","doi-asserted-by":"crossref","first-page":"11535","DOI":"10.1074\/jbc.M607999200","volume":"283","author":"F Yoshitake","year":"2008","unstructured":"Yoshitake F, Itoh S, Narita H, Ishihara K, Ebisu S (2008) Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways. J Biol Chem 283:11535\u201311540","journal-title":"J Biol Chem"},{"key":"8515_CR43","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1002\/art.24781","volume":"60","author":"R Axmann","year":"2009","unstructured":"Axmann R, Bohm C, Kronke G, Zwerina J, Smolen J, Schett G (2009) Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum 60:2747\u20132756","journal-title":"Arthritis Rheum"},{"key":"8515_CR44","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1006\/cyto.1999.0502","volume":"11","author":"A Boe","year":"1999","unstructured":"Boe A, Baiocchi M, Carbonatto M, Papoian R, Serlupi-Crescenzi O (1999) Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine 11:1057\u20131064","journal-title":"Cytokine"},{"key":"8515_CR45","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/jbmr.5650110113","volume":"11","author":"S Kotake","year":"1996","unstructured":"Kotake S, Sato K, Kim KJ et al (1996) Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 11:88\u201395","journal-title":"J Bone Miner Res"},{"key":"8515_CR46","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1002\/1529-0131(199812)41:12<2117::AID-ART6>3.0.CO;2-P","volume":"41","author":"N Takagi","year":"1998","unstructured":"Takagi N, Mihara M, Moriya Y et al (1998) Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 41:2117\u20132121","journal-title":"Arthritis Rheum"},{"key":"8515_CR47","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/art.22496","volume":"56","author":"E Jimenez-Boj","year":"2007","unstructured":"Jimenez-Boj E, Nobauer-Huhmann I, Hanslik-Schnabel B et al (2007) Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. Arthritis Rheum 56:1118\u20131124","journal-title":"Arthritis Rheum"},{"key":"8515_CR48","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1136\/ard.2007.071977","volume":"67","author":"EA Haavardsholm","year":"2008","unstructured":"Haavardsholm EA, Boyesen P, Ostergaard M, Schildvold A, Kvien TK (2008) Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann Rheum Dis 67:794\u2013800","journal-title":"Ann Rheum Dis"},{"key":"8515_CR49","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/ard.2008.088245","volume":"68","author":"ML Hetland","year":"2009","unstructured":"Hetland ML, Ejbjerg B, Horslev-Petersen K et al (2009) MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 68:384\u2013390","journal-title":"Ann Rheum Dis"},{"key":"8515_CR50","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/ard.2008.096024","volume":"68","author":"N Dalbeth","year":"2009","unstructured":"Dalbeth N, Smith T, Gray S et al (2009) Cellular characterisation of magnetic resonance imaging bone oedema in rheumatoid arthritis; implications for pathogenesis of erosive disease. Ann Rheum Dis 68:279\u2013282","journal-title":"Ann Rheum Dis"},{"key":"8515_CR51","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.21678","volume":"54","author":"JS Smolen","year":"2006","unstructured":"Smolen JS, Van Der Heijde DM, St Clair EW et al (2006) Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 54:702\u2013710","journal-title":"Arthritis Rheum"},{"key":"8515_CR52","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard.2006.068064","volume":"66","author":"N Nishimoto","year":"2007","unstructured":"Nishimoto N, Hashimoto J, Miyasaka N et al (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66:1162\u20131167","journal-title":"Ann Rheum Dis"},{"key":"8515_CR53","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J et al (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367:495\u2013507","journal-title":"N Engl J Med"},{"key":"8515_CR54","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF Vollenhoven van","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S et al (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367:508\u2013519","journal-title":"N Engl J Med"},{"key":"8515_CR55","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S et al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370:2377\u20132386","journal-title":"N Engl J Med"},{"key":"8515_CR56","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/rheumatology\/keh385","volume":"43","author":"A Stewart","year":"2004","unstructured":"Stewart A, Mackenzie LM, Black AJ, Reid DM (2004) Predicting erosive disease in rheumatoid arthritis. A longitudinal study of changes in bone density using digital X-ray radiogrammetry: a pilot study. Rheumatology (Oxford) 43:1561\u20131564","journal-title":"Rheumatology (Oxford)"},{"key":"8515_CR57","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/art.1780280105","volume":"28","author":"S Shimizu","year":"1985","unstructured":"Shimizu S, Shiozawa S, Shiozawa K, Imura S, Fujita T (1985) Quantitative histologic studies on the pathogenesis of periarticular osteoporosis in rheumatoid arthritis. Arthritis Rheum 28:25\u201331","journal-title":"Arthritis Rheum"},{"key":"8515_CR58","doi-asserted-by":"crossref","first-page":"797","DOI":"10.7326\/0003-4819-146-11-200706050-00008","volume":"146","author":"K Nishimura","year":"2007","unstructured":"Nishimura K, Sugiyama D, Kogata Y et al (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146:797\u2013808","journal-title":"Ann Intern Med"},{"key":"8515_CR59","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00296-012-2397-1","volume":"33","author":"Y Saeki","year":"2013","unstructured":"Saeki Y, Kudo-Tanaka E, Ohshima S et al (2013) Baseline anti-citrullinated peptide antibody (ACPA) titers and serum interleukin-6 (IL-6) levels possibly predict progression of bone destruction in early stages of rheumatoid arthritis (ERA). Rheumatol Int 33:451\u2013456","journal-title":"Rheumatol Int"},{"key":"8515_CR60","doi-asserted-by":"publisher","unstructured":"Hecht C., Englbrecht M., Rech J., et al. (2014) Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA. Ann Rheum Dis. doi: 10.1136\/annrheumdis-2014-205428","DOI":"10.1136\/annrheumdis-2014-205428"},{"key":"8515_CR61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11914-013-0185-9","volume":"12","author":"U Harre","year":"2014","unstructured":"Harre U, Kittan NA, Schett G (2014) Autoantibody-mediated bone loss. Curr Osteoporos Rep 12:17\u201321","journal-title":"Curr Osteoporos Rep"},{"key":"8515_CR62","doi-asserted-by":"crossref","first-page":"R64","DOI":"10.1186\/ar1926","volume":"8","author":"L Mathsson","year":"2006","unstructured":"Mathsson L, Lampa J, Mullazehi M, Ronnelid J (2006) Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells. Arthritis Res Ther 8:R64","journal-title":"Arthritis Res Ther"},{"key":"8515_CR63","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/art.23284","volume":"58","author":"C Clavel","year":"2008","unstructured":"Clavel C, Nogueira L, Laurent L et al (2008) Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum 58:678\u2013688","journal-title":"Arthritis Rheum"},{"key":"8515_CR64","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/art.27386","volume":"62","author":"MC Lu","year":"2010","unstructured":"Lu MC, Lai NS, Yu HC, Huang HB, Hsieh SC, Yu CL (2010) Anti-citrullinated protein antibodies bind surface-expressed citrullinated Grp78 on monocyte\/macrophages and stimulate tumor necrosis factor alpha production. Arthritis Rheum 62:1213\u20131223","journal-title":"Arthritis Rheum"},{"key":"8515_CR65","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1172\/JCI60975","volume":"122","author":"U Harre","year":"2012","unstructured":"Harre U, Georgess D, Bang H et al (2012) Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 122:1791\u20131802","journal-title":"J Clin Invest"},{"key":"8515_CR66","doi-asserted-by":"crossref","first-page":"10729","DOI":"10.1073\/pnas.1301001110","volume":"110","author":"M Seeling","year":"2013","unstructured":"Seeling M, Hillenhoff U, David JP et al (2013) Inflammatory monocytes and Fcgamma receptor IV on osteoclasts are critical for bone destruction during inflammatory arthritis in mice. Proc Natl Acad Sci U S A 110:10729\u201310734","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8515_CR67","doi-asserted-by":"crossref","first-page":"6651","DOI":"10.1038\/ncomms7651","volume":"6","author":"U Harre","year":"2015","unstructured":"Harre U, Lang SC, Pfeifle R et al (2015) Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nat Commun 6:6651","journal-title":"Nat Commun"},{"key":"8515_CR68","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.1129594","volume":"313","author":"Y Kaneko","year":"2006","unstructured":"Kaneko Y, Nimmerjahn F, Ravetch JV (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313:670\u2013673","journal-title":"Science"},{"key":"8515_CR69","doi-asserted-by":"crossref","first-page":"R303","DOI":"10.1186\/ar1187","volume":"6","author":"E Berglin","year":"2004","unstructured":"Berglin E, Padyukov L, Sundin U et al (2004) A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 6:R303\u2013308","journal-title":"Arthritis Res Ther"},{"key":"8515_CR70","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/art.20018","volume":"50","author":"MM Nielen","year":"2004","unstructured":"Nielen MM, van Schaardenburg D, Reesink HW et al (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50:380\u2013386","journal-title":"Arthritis Rheum"},{"key":"8515_CR71","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281\u2013297","journal-title":"Cell"},{"key":"8515_CR72","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nrg2290","volume":"9","author":"W Filipowicz","year":"2008","unstructured":"Filipowicz W, Bhattacharyya SN, Sonenberg N (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9:102\u2013114","journal-title":"Nat Rev Genet"},{"key":"8515_CR73","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s13238-012-2003-z","volume":"3","author":"X Chen","year":"2012","unstructured":"Chen X, Liang H, Zhang J, Zen K, Zhang CY (2012) Horizontal transfer of microRNAs: molecular mechanisms and clinical applications. Protein Cell 3:28\u201337","journal-title":"Protein Cell"},{"key":"8515_CR74","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.tcb.2011.12.001","volume":"22","author":"X Chen","year":"2012","unstructured":"Chen X, Liang H, Zhang J, Zen K, Zhang CY (2012) Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol 22:125\u2013132","journal-title":"Trends Cell Biol"},{"key":"8515_CR75","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/j.1600-0854.2011.01225.x","volume":"12","author":"A Bobrie","year":"2011","unstructured":"Bobrie A, Colombo M, Raposo G, Thery C (2011) Exosome secretion: molecular mechanisms and roles in immune responses. Traffic 12:1659\u20131668","journal-title":"Traffic"},{"key":"8515_CR76","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ncomms1285","volume":"2","author":"M Mittelbrunn","year":"2011","unstructured":"Mittelbrunn M, Gutierrez-Vazquez C, Villarroya-Beltri C et al (2011) Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun 2:282","journal-title":"Nat Commun"},{"key":"8515_CR77","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1172\/JCI66517","volume":"123","author":"AM Roccaro","year":"2013","unstructured":"Roccaro AM, Sacco A, Maiso P et al (2013) BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest 123:1542\u20131555","journal-title":"J Clin Invest"},{"key":"8515_CR78","first-page":"w13175","volume":"141","author":"I Duroux-Richard","year":"2011","unstructured":"Duroux-Richard I, Jorgensen C, Apparailly F (2011) miRNAs and rheumatoid arthritis - promising novel biomarkers. Swiss Med Wkly 141:w13175","journal-title":"Swiss Med Wkly"},{"key":"8515_CR79","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/art.30321","volume":"63","author":"T Nakasa","year":"2011","unstructured":"Nakasa T, Shibuya H, Nagata Y, Niimoto T, Ochi M (2011) The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis. Arthritis Rheum 63:1582\u20131590","journal-title":"Arthritis Rheum"},{"key":"8515_CR80","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1016\/j.febslet.2011.05.020","volume":"585","author":"A Ceribelli","year":"2011","unstructured":"Ceribelli A, Nahid MA, Satoh M, Chan EK (2011) MicroRNAs in rheumatoid arthritis. FEBS Lett 585:3667\u20133674","journal-title":"FEBS Lett"},{"key":"8515_CR81","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/nm.2815","volume":"18","author":"S Zhu","year":"2012","unstructured":"Zhu S, Pan W, Song X et al (2012) The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-alpha. Nat Med 18:1077\u20131086","journal-title":"Nat Med"},{"key":"8515_CR82","doi-asserted-by":"crossref","first-page":"11193","DOI":"10.1073\/pnas.1019536108","volume":"108","author":"M Kurowska-Stolarska","year":"2011","unstructured":"Kurowska-Stolarska M, Alivernini S, Ballantine LE et al (2011) MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci U S A 108:11193\u201311198","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8515_CR83","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.4049\/jimmunol.179.8.5082","volume":"179","author":"E Tili","year":"2007","unstructured":"Tili E, Michaille JJ, Cimino A et al (2007) Modulation of miR-155 and miR-125b levels following lipopolysaccharide\/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 179:5082\u20135089","journal-title":"J Immunol"},{"key":"8515_CR84","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/art.30281","volume":"63","author":"S Bluml","year":"2011","unstructured":"Bluml S, Bonelli M, Niederreiter B et al (2011) Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice. Arthritis Rheum 63:1281\u20131288","journal-title":"Arthritis Rheum"},{"key":"8515_CR85","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1182\/blood-2010-10-311415","volume":"117","author":"T Sugatani","year":"2011","unstructured":"Sugatani T, Vacher J, Hruska KA (2011) A microRNA expression signature of osteoclastogenesis. Blood 117:3648\u20133657","journal-title":"Blood"},{"key":"8515_CR86","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1016\/j.febslet.2012.06.047","volume":"586","author":"J Zhang","year":"2012","unstructured":"Zhang J, Zhao H, Chen J et al (2012) Interferon-beta-induced miR-155 inhibits osteoclast differentiation by targeting SOCS1 and MITF. FEBS Lett 586:3255\u20133262","journal-title":"FEBS Lett"},{"key":"8515_CR87","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13059-014-0561-5","volume":"16","author":"L Rica de la","year":"2015","unstructured":"de la Rica L, Garcia-Gomez A, Comet NR et al (2015) NF-kappaB-direct activation of microRNAs with repressive effects on monocyte-specific genes is critical for osteoclast differentiation. Genome Biol 16:2","journal-title":"Genome Biol"},{"key":"8515_CR88","doi-asserted-by":"publisher","unstructured":"Nakamachi Y., Ohnuma K., Uto K., Noguchi Y., Saegusa J., Kawano S. (2015) MicroRNA-124 inhibits the progression of adjuvant-induced arthritis in rats. Ann Rheum Dis. doi: 10.1136\/annrheumdis-2014-206417","DOI":"10.1136\/annrheumdis-2014-206417"},{"key":"8515_CR89","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1172\/JCI70050","volume":"124","author":"JL Crane","year":"2014","unstructured":"Crane JL, Cao X (2014) Bone marrow mesenchymal stem cells and TGF-beta signaling in bone remodeling. J Clin Invest 124:466\u2013472","journal-title":"J Clin Invest"},{"key":"8515_CR90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2011.10.044","volume":"492","author":"DG Monroe","year":"2012","unstructured":"Monroe DG, McGee-Lawrence ME, Oursler MJ, Westendorf JJ (2012) Update on Wnt signaling in bone cell biology and bone disease. Gene 492:1\u201318","journal-title":"Gene"},{"key":"8515_CR91","doi-asserted-by":"publisher","unstructured":"Sanchez-Duffhues G., Hiepen C., Knaus P., Ten Dijke P. (2015) Bone morphogenetic protein signaling in bone homeostasis. Bone. doi: 10.1016\/j.bone.2015.05.025","DOI":"10.1016\/j.bone.2015.05.025"},{"key":"8515_CR92","doi-asserted-by":"crossref","unstructured":"Regard J. B., Zhong Z., Williams B. O., Yang Y. (2012) Wnt signaling in bone development and disease: making stronger bone with Wnts. Cold Spring Harb Perspect Biol 4:12","DOI":"10.1101\/cshperspect.a007997"},{"key":"8515_CR93","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1359\/jbmr.060311","volume":"21","author":"F Morvan","year":"2006","unstructured":"Morvan F, Boulukos K, Clement-Lacroix P et al (2006) Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 21:934\u2013945","journal-title":"J Bone Miner Res"},{"key":"8515_CR94","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.bone.2006.03.017","volume":"39","author":"J Li","year":"2006","unstructured":"Li J, Sarosi I, Cattley RC et al (2006) Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39:754\u2013766","journal-title":"Bone"},{"key":"8515_CR95","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1210\/me.2003-0498","volume":"18","author":"PV Bodine","year":"2004","unstructured":"Bodine PV, Zhao W, Kharode YP et al (2004) The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol 18:1222\u20131237","journal-title":"Mol Endocrinol"},{"key":"8515_CR96","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1359\/jbmr.090719","volume":"25","author":"W Yao","year":"2010","unstructured":"Yao W, Cheng Z, Shahnazari M, Dai W, Johnson ML, Lane NE (2010) Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects. J Bone Miner Res 25:190\u2013199","journal-title":"J Bone Miner Res"},{"key":"8515_CR97","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nm1538","volume":"13","author":"D Diarra","year":"2007","unstructured":"Diarra D, Stolina M, Polzer K et al (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13:156\u2013163","journal-title":"Nat Med"},{"key":"8515_CR98","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.semarthrit.2011.01.006","volume":"41","author":"D Daoussis","year":"2011","unstructured":"Daoussis D, Andonopoulos AP (2011) The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodeling? Semin Arthritis Rheum 41:170\u2013177","journal-title":"Semin Arthritis Rheum"},{"key":"8515_CR99","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.33504","volume":"64","author":"MM Matzelle","year":"2012","unstructured":"Matzelle MM, Gallant MA, Condon KW et al (2012) Resolution of inflammation induces osteoblast function and regulates the Wnt signaling pathway. Arthritis Rheum 64:1540\u20131550","journal-title":"Arthritis Rheum"},{"key":"8515_CR100","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","volume":"280","author":"X Li","year":"2005","unstructured":"Li X, Zhang Y, Kang H et al (2005) Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883\u201319887","journal-title":"J Biol Chem"},{"key":"8515_CR101","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajmg.10401","volume":"110","author":"K Staehling-Hampton","year":"2002","unstructured":"Staehling-Hampton K, Proll S, Paeper BW et al (2002) A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet 110:144\u2013152","journal-title":"Am J Med Genet"},{"key":"8515_CR102","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/jmg.39.2.91","volume":"39","author":"W Balemans","year":"2002","unstructured":"Balemans W, Patel N, Ebeling M et al (2002) Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 39:91\u201397","journal-title":"J Med Genet"},{"key":"8515_CR103","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/jbmr.1794","volume":"28","author":"AH Lierop van","year":"2013","unstructured":"van Lierop AH, Hamdy NA, van Egmond ME, Bakker E, Dikkers FG, Papapoulos SE (2013) Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers. J Bone Miner Res 28:848\u2013854","journal-title":"J Bone Miner Res"},{"key":"8515_CR104","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","volume":"10","author":"W Balemans","year":"2001","unstructured":"Balemans W, Ebeling M, Patel N et al (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537\u2013543","journal-title":"Hum Mol Genet"},{"key":"8515_CR105","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1034\/j.1399-0004.2003.00036.x","volume":"63","author":"H Hamersma","year":"2003","unstructured":"Hamersma H, Gardner J, Beighton P (2003) The natural history of sclerosteosis. Clin Genet 63:192\u2013197","journal-title":"Clin Genet"},{"key":"8515_CR106","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","volume":"23","author":"X Li","year":"2008","unstructured":"Li X, Ominsky MS, Niu QT et al (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23:860\u2013869","journal-title":"J Bone Miner Res"},{"key":"8515_CR107","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","volume":"22","author":"DG Winkler","year":"2003","unstructured":"Winkler DG, Sutherland MK, Geoghegan JC et al (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22:6267\u20136276","journal-title":"EMBO J"},{"key":"8515_CR108","doi-asserted-by":"crossref","first-page":"272","DOI":"10.7150\/ijbs.2929","volume":"8","author":"G Chen","year":"2012","unstructured":"Chen G, Deng C, Li YP (2012) TGF-beta and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci 8:272\u2013288","journal-title":"Int J Biol Sci"},{"key":"8515_CR109","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ydbio.2010.01.008","volume":"340","author":"T Gaur","year":"2010","unstructured":"Gaur T, Hussain S, Mudhasani R et al (2010) Dicer inactivation in osteoprogenitor cells compromises fetal survival and bone formation, while excision in differentiated osteoblasts increases bone mass in the adult mouse. Dev Biol 340:10\u201321","journal-title":"Dev Biol"},{"key":"8515_CR110","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1083\/jcb.201201057","volume":"197","author":"J Wei","year":"2012","unstructured":"Wei J, Shi Y, Zheng L et al (2012) miR-34s inhibit osteoblast proliferation and differentiation in the mouse by targeting SATB2. J Cell Biol 197:509\u2013521","journal-title":"J Cell Biol"},{"key":"8515_CR111","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nrendo.2011.234","volume":"8","author":"JB Lian","year":"2012","unstructured":"Lian JB, Stein GS, van Wijnen AJ et al (2012) MicroRNA control of bone formation and homeostasis. Nat Rev Endocrinol 8:212\u2013227","journal-title":"Nat Rev Endocrinol"},{"key":"8515_CR112","doi-asserted-by":"crossref","first-page":"19879","DOI":"10.1073\/pnas.1007698107","volume":"107","author":"MQ Hassan","year":"2010","unstructured":"Hassan MQ, Gordon JA, Beloti MM et al (2010) A network connecting Runx2, SATB2, and the miR-23a\u2009\u223c\u200927a\u2009\u223c\u200924-2 cluster regulates the osteoblast differentiation program. Proc Natl Acad Sci U S A 107:19879\u201319884","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8515_CR113","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1136\/ard.2008.097048","volume":"68","author":"DU Moller","year":"2009","unstructured":"Moller DU, Boonen A, Hetland ML et al (2009) Erosive progression is minimal, but erosion healing rare, in patients with rheumatoid arthritis treated with adalimumab. A 1 year investigator-initiated follow-up study using high-resolution computed tomography as the primary outcome measure. Ann Rheum Dis 68:1585\u20131590","journal-title":"Ann Rheum Dis"},{"key":"8515_CR114","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/ard.2009.123729","volume":"70","author":"UM Dohn","year":"2011","unstructured":"Dohn UM, Ejbjerg B, Boonen A et al (2011) No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study. Ann Rheum Dis 70:252\u2013258","journal-title":"Ann Rheum Dis"},{"key":"8515_CR115","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1136\/ard.2010.148395","volume":"70","author":"S Finzel","year":"2011","unstructured":"Finzel S, Rech J, Schmidt S et al (2011) Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion. Ann Rheum Dis 70:1587\u20131593","journal-title":"Ann Rheum Dis"},{"key":"8515_CR116","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2011-201075","volume":"72","author":"S Finzel","year":"2013","unstructured":"Finzel S, Rech J, Schmidt S, Engelke K, Englbrecht M, Schett G (2013) Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study. Ann Rheum Dis 72:396\u2013400","journal-title":"Ann Rheum Dis"},{"key":"8515_CR117","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/endo.141.11.7739","volume":"141","author":"L Gilbert","year":"2000","unstructured":"Gilbert L, He X, Farmer P et al (2000) Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 141:3956\u20133964","journal-title":"Endocrinology"},{"key":"8515_CR118","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1074\/jbc.M106339200","volume":"277","author":"L Gilbert","year":"2002","unstructured":"Gilbert L, He X, Farmer P et al (2002) Expression of the osteoblast differentiation factor RUNX2 (Cbfa1\/AML3\/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem 277:2695\u20132701","journal-title":"J Biol Chem"},{"key":"8515_CR119","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1074\/jbc.M509430200","volume":"281","author":"H Kaneki","year":"2006","unstructured":"Kaneki H, Guo R, Chen D et al (2006) Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J Biol Chem 281:4326\u20134333","journal-title":"J Biol Chem"},{"key":"8515_CR120","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1359\/jbmr.1998.13.5.793","volume":"13","author":"RL Jilka","year":"1998","unstructured":"Jilka RL, Weinstein RS, Bellido T, Parfitt AM, Manolagas SC (1998) Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res 13:793\u2013802","journal-title":"J Bone Miner Res"},{"key":"8515_CR121","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/jbmr.5650020612","volume":"2","author":"P Stashenko","year":"1987","unstructured":"Stashenko P, Dewhirst FE, Rooney ML, Desjardins LA, Heeley JD (1987) Interleukin-1 beta is a potent inhibitor of bone formation in vitro. J Bone Miner Res 2:559\u2013565","journal-title":"J Bone Miner Res"},{"key":"8515_CR122","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2119\/molmed.2012.00058","volume":"19","author":"NE Hengartner","year":"2013","unstructured":"Hengartner NE, Fiedler J, Ignatius A, Brenner RE (2013) IL-1beta inhibits human osteoblast migration. Mol Med 19:36\u201342","journal-title":"Mol Med"},{"key":"8515_CR123","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1210\/en.2004-1167","volume":"146","author":"XH Liu","year":"2005","unstructured":"Liu XH, Kirschenbaum A, Yao S, Levine AC (2005) Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin\/receptor activator of nuclear factor-{kappa}B (RANK) ligand\/RANK system. Endocrinology 146:1991\u20131998","journal-title":"Endocrinology"},{"key":"8515_CR124","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1359\/jbmr.090320","volume":"24","author":"NC Walsh","year":"2009","unstructured":"Walsh NC, Reinwald S, Manning CA et al (2009) Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res 24:1572\u20131585","journal-title":"J Bone Miner Res"},{"key":"8515_CR125","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/annrheumdis-2012-202184","volume":"72","author":"DP Rooy de","year":"2013","unstructured":"de Rooy DP, Yeremenko NG, Wilson AG et al (2013) Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. Ann Rheum Dis 72:769\u2013775","journal-title":"Ann Rheum Dis"},{"key":"8515_CR126","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nm.3586","volume":"20","author":"B Yu","year":"2014","unstructured":"Yu B, Chang J, Liu Y et al (2014) Wnt4 signaling prevents skeletal aging and inflammation by inhibiting nuclear factor-kappaB. Nat Med 20:1009\u20131017","journal-title":"Nat Med"},{"key":"8515_CR127","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1172\/JCI23738","volume":"115","author":"RJ Lories","year":"2005","unstructured":"Lories RJ, Derese I, Luyten FP (2005) Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 115:1571\u20131579","journal-title":"J Clin Invest"},{"key":"8515_CR128","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.rdc.2012.08.003","volume":"38","author":"RJ Lories","year":"2012","unstructured":"Lories RJ, Schett G (2012) Pathophysiology of new bone formation and ankylosis in spondyloarthritis. Rheum Dis Clin North Am 38:555\u2013567","journal-title":"Rheum Dis Clin North Am"},{"key":"8515_CR129","doi-asserted-by":"crossref","first-page":"12097","DOI":"10.1073\/pnas.1302703111","volume":"111","author":"L Yang","year":"2014","unstructured":"Yang L, Tsang KY, Tang HC, Chan D, Cheah KS (2014) Hypertrophic chondrocytes can become osteoblasts and osteocytes in endochondral bone formation. Proc Natl Acad Sci U S A 111:12097\u201312102","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8515_CR130","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/ard.59.2.135","volume":"59","author":"M Bollow","year":"2000","unstructured":"Bollow M, Fischer T, Reisshauer H et al (2000) Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 59:135\u2013140","journal-title":"Ann Rheum Dis"},{"key":"8515_CR131","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1002\/art.24888","volume":"60","author":"H Appel","year":"2009","unstructured":"Appel H, Ruiz-Heiland G, Listing J et al (2009) Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 60:3257\u20133262","journal-title":"Arthritis Rheum"},{"key":"8515_CR132","doi-asserted-by":"crossref","unstructured":"Tsui F. W., Tsui H. W., Las Heras F., Pritzker K. P., Inman R. D. (2013) Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis. Ann Rheum Dis 73:1873\u20131879","DOI":"10.1136\/annrheumdis-2013-203630"},{"key":"8515_CR133","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1136\/annrheumdis-2013-203345","volume":"72","author":"XX Chen","year":"2013","unstructured":"Chen XX, Baum W, Dwyer D et al (2013) Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis. Ann Rheum Dis 72:1732\u20131736","journal-title":"Ann Rheum Dis"},{"key":"8515_CR134","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1136\/ard.2008.102046","volume":"69","author":"S Uderhardt","year":"2010","unstructured":"Uderhardt S, Diarra D, Katzenbeisser J et al (2010) Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis 69:592\u2013597","journal-title":"Ann Rheum Dis"},{"key":"8515_CR135","doi-asserted-by":"crossref","first-page":"R253","DOI":"10.1186\/ar4096","volume":"14","author":"KR Haynes","year":"2012","unstructured":"Haynes KR, Pettit AR, Duan R et al (2012) Excessive bone formation in a mouse model of ankylosing spondylitis is associated with decreases in Wnt pathway inhibitors. Arthritis Res Ther 14:R253","journal-title":"Arthritis Res Ther"},{"key":"8515_CR136","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/annrheumdis-2011-200216","volume":"71","author":"GR Heiland","year":"2012","unstructured":"Heiland GR, Appel H, Poddubnyy D et al (2012) High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis 71:572\u2013574","journal-title":"Ann Rheum Dis"},{"key":"8515_CR137","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3899\/jrheum.131199","volume":"41","author":"E Klingberg","year":"2014","unstructured":"Klingberg E, Nurkkala M, Carlsten H, Forsblad-d'Elia H (2014) Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis. J Rheumatol 41:1349\u20131356","journal-title":"J Rheumatol"},{"key":"8515_CR138","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.3899\/jrheum.100200","volume":"37","author":"HA Chen","year":"2010","unstructured":"Chen HA, Chen CH, Lin YJ et al (2010) Association of bone morphogenetic proteins with spinal fusion in ankylosing spondylitis. J Rheumatol 37:2126\u20132132","journal-title":"J Rheumatol"},{"key":"8515_CR139","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/03009740701774941","volume":"37","author":"MC Park","year":"2008","unstructured":"Park MC, Park YB, Lee SK (2008) Relationship of bone morphogenetic proteins to disease activity and radiographic damage in patients with ankylosing spondylitis. Scand J Rheumatol 37:200\u2013204","journal-title":"Scand J Rheumatol"},{"key":"8515_CR140","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jbspin.2006.11.005","volume":"74","author":"D Wendling","year":"2007","unstructured":"Wendling D, Cedoz JP, Racadot E, Dumoulin G (2007) Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 74:304\u2013305","journal-title":"Joint Bone Spine"},{"key":"8515_CR141","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.molimm.2013.07.013","volume":"57","author":"RA Colbert","year":"2014","unstructured":"Colbert RA, Tran TM, Layh-Schmitt G (2014) HLA-B27 misfolding and ankylosing spondylitis. Mol Immunol 57:44\u201351","journal-title":"Mol Immunol"},{"key":"8515_CR142","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","volume":"18","author":"JP Sherlock","year":"2012","unstructured":"Sherlock JP, Joyce-Shaikh B, Turner SP et al (2012) IL-23 induces spondyloarthropathy by acting on ROR-gammat\u2009+\u2009CD3\u2009+\u2009CD4-CD8- entheseal resident T cells. Nat Med 18:1069\u20131076","journal-title":"Nat Med"},{"key":"8515_CR143","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1046\/j.1469-7580.2001.19950503.x","volume":"199","author":"M Benjamin","year":"2001","unstructured":"Benjamin M, McGonagle D (2001) The anatomical basis for disease localisation in seronegative spondyloarthropathy at entheses and related sites. J Anat 199:503\u2013526","journal-title":"J Anat"},{"key":"8515_CR144","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.molimm.2013.06.010","volume":"57","author":"JP Sherlock","year":"2014","unstructured":"Sherlock JP, Buckley CD, Cua DJ (2014) The critical role of interleukin-23 in spondyloarthropathy. Mol Immunol 57:38\u201343","journal-title":"Mol Immunol"},{"key":"8515_CR145","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202135","volume":"72","author":"L Praet Van","year":"2013","unstructured":"Van Praet L, Van den Bosch FE, Jacques P et al (2013) Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis 72:414\u2013417","journal-title":"Ann Rheum Dis"},{"key":"8515_CR146","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1136\/annrheumdis-2012-202925","volume":"73","author":"F Ciccia","year":"2014","unstructured":"Ciccia F, Accardo-Palumbo A, Rizzo A et al (2014) Evidence that autophagy, but not the unfolded protein response, regulates the expression of IL-23 in the gut of patients with ankylosing spondylitis and subclinical gut inflammation. Ann Rheum Dis 73:1566\u20131574","journal-title":"Ann Rheum Dis"},{"key":"8515_CR147","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/art.38291","volume":"66","author":"JA Smith","year":"2014","unstructured":"Smith JA, Colbert RA (2014) Review: The interleukin-23\/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. Arthritis Rheumatol 66:231\u2013241","journal-title":"Arthritis Rheumatol"},{"key":"8515_CR148","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00011-011-0398-2","volume":"61","author":"YH Lee","year":"2012","unstructured":"Lee YH, Choi SJ, Ji JD, Song GG (2012) Associations between interleukin-23R polymorphisms and ankylosing spondylitis susceptibility: a meta-analysis. Inflamm Res 61:143\u2013149","journal-title":"Inflamm Res"},{"key":"8515_CR149","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.4238\/2014.June.18.10","volume":"13","author":"YK Kang","year":"2014","unstructured":"Kang YK, Zhang MC (2014) IL-23 promotes osteoclastogenesis in osteoblast-osteoclast co-culture system. Genet Mol Res 13:4673\u20134679","journal-title":"Genet Mol Res"},{"key":"8515_CR150","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1002\/eji.200838192","volume":"38","author":"L Chen","year":"2008","unstructured":"Chen L, Wei XQ, Evans B, Jiang W, Aeschlimann D (2008) IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kappaB (RANK) expression in myeloid precursor cells. Eur J Immunol 38:2845\u20132854","journal-title":"Eur J Immunol"},{"key":"8515_CR151","doi-asserted-by":"crossref","first-page":"R96","DOI":"10.1186\/ar2297","volume":"9","author":"T Yago","year":"2007","unstructured":"Yago T, Nanke Y, Kawamoto M et al (2007) IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther 9:R96","journal-title":"Arthritis Res Ther"},{"key":"8515_CR152","first-page":"2155","volume":"28","author":"D McGonagle","year":"2001","unstructured":"McGonagle D, Stockwin L, Isaacs J, Emery P (2001) An enthesitis based model for the pathogenesis of spondyloarthropathy. additive effects of microbial adjuvant and biomechanical factors at disease sites. J Rheumatol 28:2155\u20132159","journal-title":"J Rheumatol"},{"key":"8515_CR153","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/annrheumdis-2013-203643","volume":"73","author":"P Jacques","year":"2014","unstructured":"Jacques P, Lambrecht S, Verheugen E et al (2014) Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann Rheum Dis 73:437\u2013445","journal-title":"Ann Rheum Dis"},{"key":"8515_CR154","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23471","volume":"58","author":"D Heijde van der","year":"2008","unstructured":"van der Heijde D, Landewe R, Einstein S et al (2008) Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 58:1324\u20131331","journal-title":"Arthritis Rheum"},{"key":"8515_CR155","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/art.23901","volume":"58","author":"D Heijde van der","year":"2008","unstructured":"van der Heijde D, Landewe R, Baraliakos X et al (2008) Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 58:3063\u20133070","journal-title":"Arthritis Rheum"},{"key":"8515_CR156","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1186\/ar2794","volume":"11","author":"D Heijde van der","year":"2009","unstructured":"van der Heijde D, Salonen D, Weissman BN et al (2009) Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 11:R127","journal-title":"Arthritis Res Ther"},{"key":"8515_CR157","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","volume":"65","author":"N Haroon","year":"2013","unstructured":"Haroon N, Inman RD, Learch TJ et al (2013) The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 65:2645\u20132654","journal-title":"Arthritis Rheum"},{"key":"8515_CR158","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2012-202698","volume":"73","author":"X Baraliakos","year":"2014","unstructured":"Baraliakos X, Haibel H, Listing J, Sieper J, Braun J (2014) Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 73:710\u2013715","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-015-8515-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-015-8515-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-015-8515-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T12:00:34Z","timestamp":1718107234000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-015-8515-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,28]]},"references-count":158,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["8515"],"URL":"https:\/\/doi.org\/10.1007\/s12016-015-8515-6","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,28]]}}}